Addressing mental health need after COVID-19: a systematic review of remote EMDR therapy studies as an emerging option.

Addressing mental health need after COVID-19: a systematic review of remote EMDR therapy studies as an emerging option.

Publication date: Nov 10, 2023

The COVID-19 pandemic has been associated with a substantial rise in mental health challenges, prompting a need for accessible and effective therapeutic interventions. This review summarizes the evidence on remote Eye Movement Desensitization and Reprocessing (EMDR) therapy delivered in response to the increased need. A systematic review was conducted following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. Databases including PsychINFO, EMBASE, MEDLINE, and Web of Science were searched to identify studies assessing the efficacy of EMDR therapy administered online. Sixteen articles meeting the inclusion criteria were selected, involving 1,231 participants across various age groups. Studies covered remote individual and group EMDR sessions and self-administered computerized protocols. Findings indicate promising outcomes in reducing PTSD symptoms, anxiety, and depression. The analysis of the selected studies demonstrates the feasibility and potential efficacy of online EMDR as an accessible therapeutic option for addressing mental health difficulties, particularly during times of limited in-person interaction. However, the studies revealed limitations such as small sample sizes, absence of control groups, and reliance on self-reported measures. Systematic review registration: The present review was registered on “The International Database to Register Your Systematic Reviews” (INPLASY) with the registration number 2023120018 and DOI number 10. 37766/inplasy2023. 2.0068.

Open Access PDF

Concepts Keywords
Databases EMDR therapy
Inplasy2023 mental health
Pandemic online EMDR
Therapy online therapy
remote EMDR
self-help

Semantics

Type Source Name
disease MESH COVID-19
disease VO effective
disease MESH PTSD
pathway REACTOME Reproduction
disease MESH suicide
disease MESH cognitive impairments
disease MESH infection
drug DRUGBANK Methionine
disease VO population
drug DRUGBANK Bean
disease MESH chronic pain
disease VO effectiveness
disease VO Gap
disease VO protocol
disease IDO process
disease VO report
drug DRUGBANK Indoleacetic acid
disease MESH Anxiety Disorder
disease MESH burnout
disease MESH Mental Illness
disease IDO intervention
disease VO viability
drug DRUGBANK Etoperidone
disease MESH syndrome
drug DRUGBANK Sodium lauryl sulfate
disease IDO symptom
disease MESH acute stress disorder
disease MESH emergency
disease VO time
disease VO efficient
disease MESH social stigmas
disease MESH emotional distress
disease MESH dementia
disease MESH psychosis
disease MESH functional neurological disorder
disease IDO quality
drug DRUGBANK Trestolone
drug DRUGBANK MK-212
disease MESH intellectual disabilities
disease MESH Violence
disease MESH bipolar disorder

Original Article

(Visited 1 times, 1 visits today)